advertisement
Abstract #106250 Published in IGR 23-3
Comparison of Soluble and Liposome Encapsulated, Sustained Release Latanoprost for Focal Adipose Reduction
Loder S; Sukinik J; Cannon M; Guerrero DT; Seman S; Lee P; Nerone WV; Shivakumar A; Ricketts R; Yu TB; Kokai LFacial plastic surgery & aesthetic medicine 2023; 25: 250-257
To address the lack of non-cytotoxic, non-surgical options to treat undesirable focal adiposity of the face, we propose use of the anti-glaucoma medication and prostaglandin F2α analogue latanoprost, which has a well-described side effect of periorbital adipose shrinkage. To evaluate the safety and efficacy of soluble and liposomal latanoprost for focal fat reduction. To compare efficacy, single administrations of either the FDA-approved cytolytic drug deoxycholic acid (DOCA), latanoprost, or liposomal latanoprost were injected into ob/ob mouse inguinal fat pads. Study outcomes included mouse weight, inguinal fat pad volume, architecture, and cytotoxicity. Both DOCA and soluble latanoprost significantly reduced inguinal fat pad volume whereas liposome encapsulation reduced inguinal fat pad volume insignificantly over the 14-day study period. Hematoxylin and eosin demonstrated effective reduction in adipocyte volume without histologic evidence of cytolysis or inflammation whereas DOCA caused dermal ulcerations, adipocyte lysis, and increased tissue inflammation. Latanoprost reduced fat volume without inducing cell lysis or inflammation.
Department of Plastic Surgery and University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Full article